Influenza Antiviral Use in Patients Hospitalized With Laboratory-Confirmed Influenza in the United States, FluSurv-NET, 2015-2019

Mark W Tenforde¹, Charisse N Cummings¹, Alissa C O'Halloran¹, Gretchen Rothrock², Pam Daily Kirley², Nisha B Alden³, James Meek^{4

5}, Kimberly Yousey-Hindes^{4

5}, Kyle P Openo^{6

7

8}, Evan J Anderson^{6

7

8}, Maya L Monroe⁹, Sue Kim¹⁰, Val Tellez Nunez¹⁰, Melissa McMahon¹¹, Chelsea McMullen¹², Sarah A Khanlian¹³, Nancy L Spina¹⁴, Alison Muse¹⁴, Maria A Gaitán¹⁵, Christina B Felsen¹⁵, Krista Lung¹⁶, Eli Shiltz¹⁶, Melissa Sutton¹⁷, Ann Thomas¹⁷, H Keipp Talbot¹⁸, William Schaffner¹⁸, Andrea Price¹⁹, Ryan Chatelain¹⁹, Carrie Reed¹, Shikha Garg¹

Affiliations

¹ Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
² California Emerging Infections Program, Oakland, California, USA.
³ Colorado Department of Public Health and Environment, Denver, Colorado, USA.
⁴ Connecticut Emerging Infections Program, New Haven, Connecticut, USA.
⁵ Yale School of Public Health, New Haven, Connecticut, USA.
⁶ Georgia Emerging Infections Program, Atlanta, Georgia, USA.
⁷ Atlanta Veterans Affairs Medical Center, Atlanta, Georgia, USA.
⁸ Emory University School of Medicine, Atlanta, Georgia, USA.
⁹ Maryland Department of Health, Baltimore, Maryland, USA.
¹⁰ Michigan Department of Health and Human Services, Lansing, Michigan, USA.
¹¹ Minnesota Department of Health, St. Paul, Minnesota, USA.
¹² New Mexico Department of Health, Albuquerque, New Mexico, USA.
¹³ University of New Mexico Health Science Center, Santa Fe, New Mexico, USA.
¹⁴ New York State Department of Health, Albany, New York, USA.
¹⁵ University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
¹⁶ Ohio Department of Health, Columbus, Ohio, USA.
¹⁷ Oregon Health Authority, Portland, Oregon, USA.
¹⁸ Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
¹⁹ Salt Lake County Health Department, Salt Lake City, Utah, USA.

PMID: 36686630
PMCID: PMC9846184
DOI: 10.1093/ofid/ofac681

Influenza Antiviral Use in Patients Hospitalized With Laboratory-Confirmed Influenza in the United States, FluSurv-NET, 2015-2019

Mark W Tenforde et al. Open Forum Infect Dis. 2022.

. 2022 Dec 19;10(1):ofac681.

doi: 10.1093/ofid/ofac681. eCollection 2023 Jan.

Authors

Affiliations

¹ Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
² California Emerging Infections Program, Oakland, California, USA.
³ Colorado Department of Public Health and Environment, Denver, Colorado, USA.
⁴ Connecticut Emerging Infections Program, New Haven, Connecticut, USA.
⁵ Yale School of Public Health, New Haven, Connecticut, USA.
⁶ Georgia Emerging Infections Program, Atlanta, Georgia, USA.
⁷ Atlanta Veterans Affairs Medical Center, Atlanta, Georgia, USA.
⁸ Emory University School of Medicine, Atlanta, Georgia, USA.
⁹ Maryland Department of Health, Baltimore, Maryland, USA.
¹⁰ Michigan Department of Health and Human Services, Lansing, Michigan, USA.
¹¹ Minnesota Department of Health, St. Paul, Minnesota, USA.
¹² New Mexico Department of Health, Albuquerque, New Mexico, USA.
¹³ University of New Mexico Health Science Center, Santa Fe, New Mexico, USA.
¹⁴ New York State Department of Health, Albany, New York, USA.
¹⁵ University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
¹⁶ Ohio Department of Health, Columbus, Ohio, USA.
¹⁷ Oregon Health Authority, Portland, Oregon, USA.
¹⁸ Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
¹⁹ Salt Lake County Health Department, Salt Lake City, Utah, USA.

PMID: 36686630
PMCID: PMC9846184
DOI: 10.1093/ofid/ofac681

Abstract

From surveillance data of patients hospitalized with laboratory-confirmed influenza in the United States during the 2015-2016 through 2018-2019 seasons, initiation of antiviral treatment increased from 86% to 94%, with increases seen across all age groups. However, 62% started therapy ≥3 days after illness onset, driven by late presentation to care.

Keywords: antiviral; baloxavir; hospital; influenza; oseltamivir; treatment delay.

Published by Oxford University Press on behalf of Infectious Diseases Society of America 2022.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. E.A. has received received grants for clinical trials from Pfizer, Merck, PaxVax, Micron, Sanofi-Pasteur, Janssen, MedImmune, and GSK, has been a consultant for Sanofi-Pasteur, Pfizer, Medscape, Janssen, GSK, and Moderna, has been a member of the data safety monitoring board for Kentucky Bioprocessing and Sanofi-Pasteur, and has been a member of the endpoint adjudication committee for WCG and ACI Clinical. His institution has also received funding from the NIH to conduct clinical trials of COVID-19 vaccines. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Figures

**Figure 1.**
Percentage of hospitalized patients with laboratory-confirmed influenza who received influenza antiviral therapy by season and age,^a FluSurv-NET, 2015–2016 through 2018–2019. ^aWeighted percentages used to account for sampling methods; Cochran-Armitage test for trend suggested an increase in influenza antiviral use over time across all age groups (P < .001).

See this image and copyright information in PMC

References

1. Centers for Disease Control and Prevention . Disease burden of influenza. Available at: https://www.cdc.gov/flu/about/burden/index.html. Accessed December 11, 2020.
1. McGeer A, Green KA, Plevneshi A, et al. . Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007; 45:1568–75. - PubMed
1. Lee N, Choi KW, Chan PK, et al. . Outcomes of adults hospitalised with severe influenza. Thorax 2010; 65:510–5. - PubMed
1. Uyeki TM, Bernstein HH, Bradley JS, et al. . Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenzaa. Clin Infect Dis 2019; 68:e1–47. - PMC - PubMed
1. Chaves SS, Pérez A, Miller L, et al. . Impact of prompt influenza antiviral treatment on extended care needs after influenza hospitalization among community-dwelling older adults. Clin Infect Dis 2015; 61:1807–14. - PubMed

Grants and funding

UL1 TR001863/TR/NCATS NIH HHS/United States

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Influenza Antiviral Use in Patients Hospitalized With Laboratory-Confirmed Influenza in the United States, FluSurv-NET, 2015-2019

Affiliations

Influenza Antiviral Use in Patients Hospitalized With Laboratory-Confirmed Influenza in the United States, FluSurv-NET, 2015-2019

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

References

Grants and funding

LinkOut - more resources

Full Text Sources